Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 10/20 | 0.33 |
| ▸ | CCNC | P24863 | 9/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.32 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620331 | 0.86 | OTUD7B (0.35) | OTUD7BCDK8CCNCSPRCDK19 | |
| SCHEMBL18702126 | 0.79 | OTUD7B (0.43) | OTUD7BCDK8CCNCSPRCALCRL | |
| SCHEMBL19852883 | 0.77 | ITGB3 (0.42) | OTUD7BCALCRL | |
| SCHEMBL19852926 | 0.76 | GRIN2B (0.31) | — | |
| SCHEMBL29890275 | 0.74 | OTUD7B (0.46) | OTUD7BCDK8CCNCSPRCALCRL | |
| SCHEMBL24338486 | 0.72 | OTUD7B (0.36) | OTUD7BCDK8CCNCSPRCALCRL | |
| SCHEMBL745671 | 0.72 | OTUD7B (0.40) | OTUD7BCDK8CCNCSPRCDK19 | |
| SCHEMBL19852884 | 0.71 | OTUD7B (0.39) | OTUD7BCDK8CCNCSPRCDK19 | |
| SCHEMBL18711886 | 0.71 | OTUD7B (0.46) | OTUD7BCDK8CCNCSPRTYK2 | |
| SCHEMBL19852881 | 0.70 | OTUD7B (0.43) | OTUD7BCDK8CCNCSPRCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885CDK8 1003/4885CCNC 2764/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885CDK8 1003/4885CCNC 2764/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885CDK8 1003/4885CCNC 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.